6533b821fe1ef96bd127ad63
RESEARCH PRODUCT
An early bolus of hypertonic saline hydroxyethyl starch improves long-term outcome after global cerebral ischemia.
Ansgar M. BrambrinkRuediger R. NoppensOliver KempskiInes P. KoernerMichael ChristAxel Heimannsubject
MaleTime FactorsTraumatic brain injurymedicine.medical_treatmentIschemiaPlasma SubstitutesBlood PressureHydroxyethyl starchCritical Care and Intensive Care MedicineWeight GainBrain IschemiaHydroxyethyl Starch DerivativesBolus (medicine)Intensive caremedicineAnimalsRats WistarSalineNeuronsSaline Solution HypertonicCell Deathbusiness.industrySodiumBrainmedicine.diseaseHypertonic salineRatsCerebral blood flowHematocritAnesthesiaReperfusionPotassiumbusinessmedicine.drugdescription
Objective: The beneficial effect of hypertonic saline solutions in the emergency treatment of shock and traumatic brain injury is well described. The present study determines effects of a single bolus of hypertonic saline on long-term survival, neurologic function, and neuronal survival 10 days after global cerebral ischemia. In addition, we evaluated the therapeutic window for hypertonic saline treatment (early vs. delayed application). Design: Laboratory experiment. Setting: University laboratory. Subjects: Male Wistar rats weighing 240‐330 g. Interventions: Rats were submitted to temporal global cerebral ischemia using temporary bilateral carotid occlusion combined with hypobaric hypotension. Animals received 7.5% saline/6% hydroxyethyl starch (HHS) or vehicle (NaCl 0.9%) at either 1.5 mins (early treatment) or 31.5 mins (delayed treatment) of reperfusion. Regional cerebral blood flow (rCBF) and physiologic variables were measured during insult and early reperfusion. Animal survival and neurologic function were evaluated throughout the 10-day observation period. Quantification of brain injury was performed on day 10. Measurements and Main Results: Early treatment with HHS resulted in a robust restoration of rCBF after ischemia, reduced postischemic mortality by 77% (9% vs. 39% in vehicle-treated controls), ameliorated neurologic performance (Neuro-Deficit-Score 10 days after insult, 96 0.7 vs. 85 1.4, mean SE), and almost blunted neuronal cell death (hippocampal CA1, 2150 191 vs. 884 141 neurons/mm 2 ; cortex, 1746 91 vs. 1060 112). In contrast, delayed treatment resulted in no sustained effects. Conclusions: Timing of HHS treatment is critical after experimental global cerebral ischemia to reduce mortality, improve neurologic function, and neuronal survival. Our results suggest that early application of HHS may be a potential neuroprotective strategy after global cerebral ischemia. (Crit Care Med 2006; 34:2194‐2200)
year | journal | country | edition | language |
---|---|---|---|---|
2006-08-01 | Critical care medicine |